Literature DB >> 8701029

Vasopressin potentiation of the melatonin synthetic pathway via specific V1a receptors in the rat pineal gland.

V Simonneaux1, R Kozak, Y Arsenijévic, P Pévet.   

Abstract

The pineal gland releases the "time-keeping' hormone melatonin following a rhythmic sympathetic input which translates light information. The aim of this work was to study the role and mechanism of action of the central vasopressinergic input on pineal cAMP-dependent melatonin synthesis in the rat. The pineal was found to display vasopressin receptors of the V1a subtype, as the V1a antagonist [125I]HO-LVA bound in a saturable manner to pineal membranes with a high affinity (kd = 10 pM) and a maximal binding capacity (B(max)) of 13 fmol/mg protein. Vasopressin was able to displace [125I]HO-LVA binding in a dose-dependent manner (k(i) = 1.9 nM). Vasopressin had no effect on the basal cAMP level and melatonin secretion in cultured rat pinealocytes. However, it clearly and dose-dependently (EC50 = 7 nM) potentiated by 2-3 times cAMP accumulation and by 1.5-2.5 times melatonin secretion induced by moderate noradrenergic stimulation. On strongly stimulated pinealocytes, however, vasopressin could potentiate cAMP accumulation, but not melatonin secretion. The potentiatory effect of vasopressin was inhibited in the presence of the V1a antagonist. These results indicate that vasopressin is a potent modulator of rat pineal synthetic activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701029     DOI: 10.1016/0167-0115(95)00139-5

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  2 in total

Review 1.  The rhythm and blues of gene expression in the rodent pineal gland.

Authors:  Magdalena Karolczak; Horst-Werner Korf; Jörg H Stehle
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

2.  The influence of vasopressin deficiency and acute desmopressin administration on melatonin secretion in patients with central diabetes insipidus.

Authors:  S B Catrina; R Rotarus; I-L Wivall; M Coculescu; K Brismar
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.